Biopharmaceutical company Suven Life Sciences Ltd has announced it has secured product patents in Europe, Hong Kong, Japan, Macau and South Korea and from ARIPO (African Regional Intellectual Property Organization), for New Chemical Entities (NCE’s) useful in central nervous system (CNS) therapy.
In a filing with BSE, the company stated that these patents, valid until 2031, are useful in the treatment of cognitive impairment associated with neurodegenerative disorders. With these new patents, Suven has one product patent in ARIPO, nineteen from Europe, eighteen from Hong Kong, South Korea and Japan and seven from Macau.
Suven achieved these IPs through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II
“Our pipeline of molecules in CNS arena being developed for cognitive disorders have high unmet medical need with huge market potential globally,” according to Venkat Jasti, CEO of Suven.